| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w20469 |
| 来源ID | Working Paper 20469 |
| Poor Quality Drugs and Global Trade: A Pilot Study | |
| Roger Bate; Ginger Zhe Jin; Aparna Mathur; Amir Attaran | |
| 发表日期 | 2014-09-05 |
| 出版年 | 2014 |
| 语种 | 英语 |
| 摘要 | Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries. We find that 10.9% of those products fail a basic assessment of active pharmaceutical ingredients (API), and the majority of the failures are substandard (7%) as they contain some correct API but the amount of API is under-dosed. The distribution of these substandard products is not random: they are more likely to be found as unregistered products in Africa than in India or non-African countries. Since this finding is robust for manufacturer-drug fixed effects, one likely explanation is that Indian pharmaceutical firms and/or their export intermediaries do indeed differentiate drug quality according to the destination of consumption. |
| 主题 | Microeconomics ; Economics of Information ; International Economics ; Trade ; Globalization and International Relations ; Health, Education, and Welfare ; Health ; Industrial Organization ; Market Structure and Firm Performance |
| URL | https://www.nber.org/papers/w20469 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/578141 |
| 推荐引用方式 GB/T 7714 | Roger Bate,Ginger Zhe Jin,Aparna Mathur,et al. Poor Quality Drugs and Global Trade: A Pilot Study. 2014. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
